None listed
Conditions
Interventions
Sponsors
Maruzen Pharmaceuticals Co., Ltd.
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1)Males equal to or more than 20 years and less than 39 years of age 2)Subjects who BMI18.5=> kg/m2 and <30kg/m2 3)Subjects who visit on schedule days 4)Subjects who recognize the object and contents of the study and submit the written informed consent
Exclusion criteria
Exclusion criteria: 1)Subjects who have systolic blood pressure <90 mmHg 2)Subjects who donated 200 mL or more of blood within 4 weeks from the start of the study 3)Subjects who donated 400 mL or more of blood within 12 weeeks from the start of the study 4)Subjects who donated 1200 mL over or more of blood within 12 months from the start of the study 5)Subjects who participated in other clinical studies in the past 4 weeks 6)Subjects who fall under any of the following items a) Subjects who have a history of severe illness and current medical history in the heart, liver, kidney, digestive organs b) Subjects who are under treatment or have a history of cardiovascular disease c) Subjects who develop diabetes d) Subjects who have allergy related to the study foods 7)Subjects who are under treatment 8)Subjects who have history of surgery on gastrointestinal part such as gastrectomy, gastrointestinal suture and intestinal resection 9)Subjects who have allergy related to the foods 10)Subjects who have experienced sickness due to blood collection 11)Subjects who have difficulty drawing blood from the peripheral vein 12)Heavy alcoholic beverager(40g alcohol/day>=) 13)Subjects who quit smoking for less than 6 months or smokers 14)Subjects whose eating habits are extremely irregular 15)Shift worker and night worker 16)Subjects who took medicine before the study 17)Subjects who use oral supplements which may affect this study 18)Subjects who the physician's judgement found difficult to consume the test foods 19)Subjects who are ineligible due to physician's judgement
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Maximum observed plasma concentration, Maximum time plasma concentration, Area under the plasma concentration-time curve from time zero to the time of the last measurable drug concentration | — |
Countries
Japan
Contacts
Public ContactToyotada Ashino
New drug research center, Inc. Clinical Research Dept.
Outcome results
None listed